<DOC>
	<DOCNO>NCT00525889</DOCNO>
	<brief_summary>This phase I trial individual diagnose type 1 diabetes within previous 3-48 month . The study test whether two immune system modify drug safe use combination immune alter effect indicate halt progression type 1 diabetes progression .</brief_summary>
	<brief_title>Proleukin Rapamune Type 1 Diabetes</brief_title>
	<detailed_description>At time diagnosis type 1 diabetes , 15-40 % beta cell may remain active healthy pancreas , capable produce insulin body need regulate blood glucose level . Because even small amount natural insulin production decrease long term effect diabetes , essential cell preserve . This trial test whether combination drug Proleukin ( IL-2 ) Rapamune ( sirolimus ) may safely administer recently diagnose type 1 diabetes patient whether cause change immune system halt autoimmune destruction remain beta cell . This drug combination find effective long-term diabetes prevention mouse model type 1 diabetes . This study phase I study individual 18-45 year age diagnose type 1 diabetes past 3-48 month . All participant treat Proleukin ( administer subcutaneously 3x per week ) 28 day Rapamune ( take orally , daily ) 12 week . The study last 12 month , additional follow-up 24 month . The majority study visit occur within first 6 month . Mixed meal tolerance test , participant take milkshake-like drink blood sample 2 4-hour period , take place initial screen visit three additional time first year . All participant also receive intensive diabetes management design maintain stable blood glucose level .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Aldesleukin</mesh_term>
	<mesh_term>Interleukin-2</mesh_term>
	<criteria>Diagnosed type 1 diabetes ( per ADA criterion ) 3 less 48 month prior enrollment ; 18 45 year age ; Positive least one islet cell autoantibody ( GAD65antibody , CA512antibody and/or ICA ) . Chronic use glucocorticoid immunosuppressive age 4 week enrollment ; History recurrent infection , autoimmune disease , cardiac disease , cataracts chronic medical condition investigator believe could compromise participant safety ; Females pregnant , lactate intend get pregnant , unwilling undergo pregnancy test study ; Males intend father pregnancy first 6 month study ; Participation another clinical study within last 30 day .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>diabetes</keyword>
	<keyword>juvenile diabetes</keyword>
	<keyword>type 1 diabetes</keyword>
	<keyword>diabetes mellitus</keyword>
	<keyword>recent onset</keyword>
	<keyword>new onset</keyword>
</DOC>